Shots:
- The NMPA has approved cadonilimab + Pt-based CT ± Avastin as a 1L treatment of persistent, recurrent, or metastatic cervical cancer
- Approval was based on the P-III (COMPASSION-16) trial assessing cadonilimab vs SoCs, which met its PFS & OS endpoints, showing efficacy in PD-L1-negative tumors (CPS <1; 27.9% vs 24.2%) with subgroup analyses demonstrating benefit regardless of PD-L1 expression or Avastin inclusion. Data was presented at IGCS 2024 & published in The Nature Reviews Clinical Oncology
- Cadonilimab, a PD-1/CTLA-4 bsAb, is being evaluated in ~30 P-II & P-III trials across various stages & subtypes of cancers, including gastric, lung, liver, cervical, & pancreatic cancers
Ref: PRNewswire | Image: Akeso |Press Release
Related News:- Akeso’s Penpulimab-kcqx Receives the US FDA’s Approval for Nasopharyngeal Carcinoma (NPC)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
